Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.
You may also be interested in...
After the hedge fund Scopia called on Acorda to investigate the possibility of a sale, the biotech's argument for its current direction faltered due to an FDA refuse-to-file letter for Inbrija. Acorda then adopted a shareholder rights plan to buy time.
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.
PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.